The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.

Blackstone follows Abingworth, but why?

Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.

But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.

As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?

Syndax’s Revuforj beats Kura in NPM1-mutated AML.